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Background: Microglia are key players for the inflammatory responses in the central nervous system. Suppression
of microglial activation and the resulting production of proinflammatory molecules are considered a promising
strategy to alleviate the progression of neurodegenerative disorders. Triptolide was demonstrated as a potent
anti-inflammatory compound both in vitro and in vivo. The present study explored potential signal pathways of
triptolide in the lipopolysaccharide (LPS)-induced inflammatory response using primary rat microglial cells.
Findings: Microglial cells were pretreated with triptolide and stimulated with LPS. To investigate the anti-inflammatory
effect of triptolide, we used Griess reagent and Western blot for NO release and iNOS expression, respectively. Moreover,
we applied microglia-conditioned medium to neuronal cells and used the MTS assay to test cell viability. We found that
triptolide inhibited LPS-induced NO and iNOS synthesis in microglial cells, which in turn protected neurons. To evaluate
the involvement of the EP2 pathway, we used real-time PCR and Western blot to determine EP2 expression. We found
that LPS induced a large increase in EP2 expression in microglia, and triptolide almost completely inhibited LPS-induced
EP2 expression. Using the selective EP2 agonist butaprost and the EP2 antagonist AH6809, we determined that triptolide
inhibited LPS-stimulated NO production in microglia mainly through the EP2 pathway. Additionally, by further treating
triptolide-treated microglia with the downstream PKA-specific activator 6-Bnz-cAMP or the Epac-specific activator
8-pCPT-2-O-Me-cAMP, we found that 6-Bnz-cAMP but not 8-pCPT-2-O-Me-cAMP increased NO production in
triptolide-LPS treated microglia. These results indicate that the EP2-PKA pathway is very important for triptolide’s effects.
Conclusions: Triptolide inhibits LPS-stimulated NO production in microglia via a signaling mechanism involving EP2
and PKA. This finding may help establish the pharmacological function of triptolide in neurodegenerative disorders.
Moreover, the observation of inflammatory EP2 signaling in primary microglia provides important evidence that EP2
regulates innate immunity in the central nervous system.
Keywords: Triptolide, EP2, Microglia, Neuroinflammation, Nitric oxideFindings
Microglia, the immune-like cells of the brain, play an
important role in inflammatory responses in the central
nervous system (CNS) [1]. The modulation of microglial
activation and their production of pro-inflammatory me-
diators and cytokines could also be a promising strategy
to alleviate the progression of neurodegenerative disor-
ders [2-5]. The cyclooxygenase-2 (COX-2) pathway me-
diates the main inflammatory responses in microglia and* Correspondence: xmwang@ccmu.edu.cn
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unless otherwise stated.is thus a very attractive target for researchers and drug
developers [6,7]. However, the deleterious cardiovascular
and cerebrovascular side effect of sustained COX-2 inhib-
ition has led to the investigation of its downstream targets
[8]. Among these targets, prostaglandin E2 (PGE2) signal-
ing via its EP2 receptor subtype appears to be a major me-
diator of inflammatory and anaphylactic reactions within
both the periphery and brain [9]. EP2 upregulation by
lipopolysaccharide (LPS) contributes to cerebral oxidative
damage and secondary neurotoxicity, effects that are usu-
ally accompanied by the induction of NO synthase (NOS)
and cyclooxygenase (COX) activities [10]. EP2 receptor
not only serves as a downstream target of COX2 but also
acts to influence COX2 and iNOS expression. It was re-
ported that iNOS and COX2 induction was completelyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing that EP2 was necessary for the induction of iNOS and
COX2 after LPS stimulation [10]. Moreover, LPS-activated
microglia-mediated neurotoxicity was completely abol-
ished in cultures lacking microglial EP2, indicating that
microglial EP2 was critical to LPS-activated microglia-
mediated neurotoxicity in vitro [10].
Triptolide is the major active component of Triptery-
gium extracts and possesses potent anti-inflammatory and
immunosuppressive properties [11]. Our group demon-
strated for the first time that triptolide possesses potent
neuroprotective properties both in vitro and in vivo [12].
In an LPS-challenged inflammation model of Parkinson’s
disease (PD), intraperitoneal injection with triptolide for
24 days significantly improved the behavior of PD rats, de-
creased DAergic neuron death, and increased DA levels in
the striatum [13]. Further study in primary cultured rat
microglia indicated that triptolide inhibits LPS-induced
microglial activation and suppresses COX-2 expression
and PGE2 release [14]. In the current study, we investi-
gated the main pathway of triptolide in LPS-induced in-
flammatory responses in primary rat microglial cells.
We found that triptolide suppressed LPS-induced nitric
oxide (NO) production and inducible NO synthase
(iNOS) synthesis in primary rat microglial cells, which in
turn protects neuronal cells from microglia-conditioned
medium-induced cell injury. Moreover, triptolide inhibits
LPS-stimulated NO production in microglia via a signal-
ing mechanism involving EP2 and PKA.
Triptolide was generously provided by Professor Peng-
FeiTu (School of Pharmaceutical Sciences, Peking Uni-
versity, Beijing, China). This white crystalline drug has a
melting point of 226°C to 240°C and, for this study, was
98% pure, as evaluated by reverse-phase high pressure li-
quid chromatography. The following materials were used
for these studies: LPS (Sigma-Aldrich, St. Louis, MO,
USA), a rabbit polyclonal antibody to iNOS (Abcam,
Cambridge, UK), a rabbit polyclonal antibody to EP2
(Cayman, MI, USA), a mouse monoclonal antibody to
CD11b (Millipore, Billerica, MA, USA), a mouse mono-
clonal antibody to GAPDH (Sigma-Aldrich), butaprost
(Cayman, MI, USA), AH6809 (Cayman, MI, USA), 6-
Bnz-cAMP (BIOLOG Life Science Institute, Bremen,
Germany), 8-pCPT-2-O-Me-cAMP (Millipore, Billerica,
MA, USA), KT5720 (Life Technologies, Carlsbad, CA,
USA), FBS (Hyclone, Logan, UT, USA), streptomycin and
penicillin (Life Technologies), 0.2-ml syringe filters, 96-
and 24-well tissue culture plates, 100-mm diameter dishes
(Corning, NY, USA), Dulbecco’s modified Eagle’s medium
(DMEM), and DMEM/F-12 (Life Technologies).
The immortalized murine BV2 microglial cell line was
purchased from Cell Resource Center, Institute of Basic
Medical Sciences, Chinese Academy of Medical Sciences
(Beijing, China). MN9D cells were kindly provided byDr. Bastian Hengerer (Novartis Institute for BioMedical
Research, Basel, Switzerland). The two cell lines were
maintained in 5% CO2 at 37°C in DMEM/F-12 supple-
mented with 10 % fetal bovine serum (FBS), 1% strepto-
mycin, and penicillin. The primary rat microglial cells
were prepared as described previously [14]. Briefly, cerebral
cortices of 0- to 1-day-old SD rats, devoid of meninges and
blood vessels, were dissociated by mild mechanical tritur-
ation. The isolated cells were seeded in 75-cm2 culture
flasks (1.5 brains in a flask) in DMEM/F-12 containing
10% FBS, 1% penicillin, and streptomycin. The cultures
were maintained at 37°C in a humidified atmosphere of 5%
CO2/95% air. Fourteen days later, the microglia were sepa-
rated from astrocytes by shaking the flasks at 180 rpm
for 2 h. The purity of the enriched microglia was >95%,
as identified by CD11b (dilution, 1:800) immunocyto-
chemical staining. All of the results are expressed as the
mean ± standard deviation (SD) of at least three inde-
pendent experiments performed in duplicate. One-way
analysis of variance (ANOVA) and Newman-Keuls mul-
tiple comparison tests were used to compare the
groups. The differences were considered to be signifi-
cant at P < 0.05. The experimental procedures in this
study were approved by the Committee on Animal Care
and Usage (Capital Medical University), and efforts
were engaged to minimize the number of animal usage
and suffering.
To confirm the anti-inflammatory effect of triptolide,
we first investigated NO and iNOS production in the
murine BV2 microglial cell line and in primary rat
microglial cells. BV2 cells and primary rat microglial
cells were cultured in 12-well plates and stimulated with
LPS (0.01 μg/mL) for 24 h. At the end of the incubation
period, supernatants were collected. NO measurements
were made using the Griess Reagent System (Promega,
Madison, WI, USA), and iNOS expression was measured
by Western blot. In BV2 cells, LPS significantly induced
NO release to 8 μM compared with 1 μM in naïve cells
(Figure 1A). In primary microglia cells, LPS significantly
induced NO release to 12 μM compared with 2 μM in
naïve cells (Figure 1B). NO is synthesized by a family of
NOS consisting of three isoforms: endothelial NOS
(eNOS), neuronal NOS (nNOS), and inducible NOS
(iNOS) [15]. Among them, NO produced from iNOS
[16] promotes the development of neurodegenerative
disorders associated with inflammation [17]. In the
present study, the increase of NO correlated well with
the induction of iNOS by LPS (Figure 1C, lane 2). BV2
cells and primary rat microglia both showed basal re-
lease of nitrite, which has been well demonstrated in
previous reports by different laboratories [18-21]. More-
over, Ryuet al. reported that neither iNOS inhibitors nor
nonselective nitric-oxide synthase inhibitors had any ef-
fect on the basal release of nitrite [22].
A B
C D
Figure 1 Triptolide suppresses NO production and iNOS expression in LPS-activated microglia. (A) Triptolide reduced NO production in
BV2 cells. BV2 cells were stimulated with LPS (0.01 μg/mL) in the presence or absence of different concentrations of triptolide (0, 12.5, 25, 50 nM) for
24 h. At the end of the incubation period, the supernatants were collected for NO measurements. (B) Triptolide reduced NO production in primary rat
microglial cells. Primary rat microglial cells were stimulated with LPS (0.01 μg/mL) in the presence or absence of triptolide (0, 12.5, 25, 50 nM) for 24 h.
At the end of the incubation period, the supernatants were collected for NO measurements. (C) Triptolide reduced iNOS expression in primary rat
microglial cells. Primary rat microglial cells were stimulated with LPS (0.01 μg/mL) in the presence or absence of triptolide (0, 12.5, 25, 50 nM) for 24 h.
The cells were then lysed to detect iNOS expression by Western blot. (D) The protein levels were quantified relative to GAPDH levels and normalized
to the LPS-stimulated group. ***P < 0.001. #P < 0.05, ##P < 0.01, and ###P < 0.001.
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induced NO and iNOS synthesis, primary rat microglial
cells were pretreated for 30 min with different concentra-
tions of triptolide and subsequently stimulated with LPS.
As shown in Figure 1A,B, triptolide dose dependently
inhibited LPS-induced NO synthesis at concentrations
from 12.5 to 50 nM. In BV2 cells, pretreatment with trip-
tolide led to a dose-dependent inhibition on LPS-induced
NO release by 6% (P < 0.05) at 12.5 nM, 22% (P < 0.01) at
25 nM, and 42% (P < 0.001) at 50 nM (Figure 1A). In pri-
mary microglial cells, pretreatment with triptolide led to a
dose-dependent inhibition on LPS-induced NO release by
30% (P < 0.05) at 12.5 nM, 41% (P < 0.01) at 25 nM, and
61% (P < 0.001) at 50 nM (Figure 1B). As further illus-
trated in Figure 1C,D, the inhibitory effect of triptolide on
NO synthesis was due to a dose-dependent inhibition of
iNOS synthesis. iNOS synthesis was inhibited at a concen-
tration of 25 nM and decreased significantly at a concen-
tration of 50 nM triptolide. These results were consistent
with a previous study in which Shen et al. reported that
30 nM triptolide inhibits NO production in LPS-activated
macrophages [23].
Activated microglia are capable of releasing neurotoxic
molecules, such as proinflammatory cytokines and toxic
oxygen and nitrogen species [24,25]. Accumulating evi-
dence shows that activated microglia can damage or kill
neurons in vitro by generating nitric oxide (NO) [26-29].As microglia secreted increased amount of NO in re-
sponse to LPS stimulation and triptolide inhibited this ef-
fect, we reasoned that triptolide may also reduce the
neuronal toxicity of LPS-stimulated microglia-conditioned
medium. MN9D cell, a fusion of neuroblastoma with mice
embryonic ventral mesencephalic cell, was treated with
the conditioned medium for 24 h, and an MTS assay
was used to assess cell viability. The medium from
microglia treated with only triptolide (50 nM) exhibited
no toxicity. However, a 24 h exposure to medium from
LPS-stimulated microglia caused a significant decrease
of MN9D cell viability to 85% of that observed for
MN9D cell exposed to medium from untreated micro-
glia. In contrast, there was no significant change of
MN9D cell viability between cells exposed to medium
from microglia treated with triptolide (50 nM) followed
by LPS and unstimulated microglia (Figure 2A). Since
triptolide alone did not change the cell viability of
MN9D cells or primary rat microglial cells (Figure 2C,
D), the results indicated that triptolide-treated micro-
glia attenuated the toxicity of the LPS-stimulated
microglia-conditioned medium to MN9D cells.
We confirm the neuroprotective effect of triptolide in
SH-SY5Y cells. The neuroblastoma cell line SH-SY5Y is
often used in the cellular model of PD due to its dopa-
minergic ability [30,31]. As shown in Figure 2B, condi-
tioned media from LPS-stimulated primary microglial
Figure 2 Triptolide protects neuronal cells from the toxicity of LPS-stimulated microglia-conditioned medium. (A) Triptolide attenuated the
toxicity of conditioned medium from LPS-stimulated microglia to MN9D cells. MN9D cells treated with conditioned medium from LPS-unstimulated
microglia, LPS-stimulated microglia with or without triptolide (50 nM), as well as triptolide alone (50 nM) treated microglia for 24 h. Cell viability was
assessed by MTS assay. (B) Triptolide attenuated the toxicity of conditioned medium from LPS-stimulated microglia to SH-SY5Y cells. SH-SY5Y cells
treated with conditioned medium from LPS-unstimulated microglia, LPS-stimulated microglia with or without triptolide (50 nM), triptolide alone (50
nM) treated microglia, as well as LPS-stimulated microglia with FeTMPyP (10 μM) for 72 h. Cell viability was assessed by MTS assay. (C) Triptolide did
not change primary rat microglial cell viability. Primary rat microglial cells were treated with triptolide (0, 6.25, 12.5, 25, 50 nM) for 24 h. Cell viability was
assessed by MTS assay. (D) Triptolide did not change MN9D cell viability. MN9D cells were treated with triptolide (0, 6.25, 12.5, 25, 50 nM) for 24 h. Cell
viability was assessed by MTS assay. **P < 0.01. #P < 0.05 and ##P < 0.01.
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SY5Y cells. Cell viability decreased to 76% of cells treated
with medium from untreated microglia. This result is
consistent with that reported by Liu et al. [32], Munch
et al. [33], and Tseng et al. [34]. In contrast, the condi-
tioned media from primary microglia cells pretreated
with triptolide prior to LPS stimulation showed little
neurotoxicity on SH-SY5Y cells, suggesting that tripto-
lide suppresses microglia-mediated neurotoxicity.
To further investigate the role of NO release from
microglia in toxicity of microglia to neuronal cells, we
treated microglial cells with peroxynitrite (ONOO-) de-
composition catalysts FeTMPyP [5,10,15,20-tetrakis(n-
methyl-4′-pyridyl) porphinato iron (III) chloride]. NO
reacts with superoxide (O2−), producing the highly re-
active and toxic peroxynitrite (ONOO-) [35]. In the
present study, we observed FeTMPyP at 10 μM blocked
the LPS-induced microglial neurotoxicity in SH-SY5Y
cells (Figure 2B), indicating peroxynitrite is a main medi-
ator for the neurotoxicity of LPS-induced microglia.
The above findings that triptolide reduced the amount
of proinflammatory factors in microglia and protected
neurons from NO stimulation may help establish thepharmacological function of triptolide in neurodegenera-
tive disorders.
Microglial EP2 is critical to the neurotoxicity caused by
the activation of cerebral innate immunity. To investigate
whether EP2 is involved in the anti-inflammatory effect of
triptolide in LPS-stimulated microglia, we first examined
EP2 expression in primary rat microglial cells. We ob-
served the basal expression of EP2 in resting microglia
(Figure 3A). As a stimulatory G protein coupled receptor
(GPCR), EP2 activation stimulates adenylate cyclase (AC).
This effect results in an elevation of cytoplasmic cAMP
levels, initiating multiple downstream events. To assess the
functionality of the EP2 receptor in microglia, the cAMP
level was determined by treating microglia with butaprost
(10 μM), a selective EP2 agonist, or with AH6809 (10 μM),
an EP2 antagonist. As shown in Figure 3B, there was a
trend of increased intracellular cAMP accumulation in
microglia treated with 10 μM butaprost for 3 h compared
to control. By contrast, the treatment of microglia with
10 μM AH6809 for 3 h decreased the intracellular
cAMP accumulation. Butaprost alone increased the
basal level of microglia NO production (Figure 3C).
This may be due to the iNOS expression influenced by
Figure 3 EP2 signaling pathway regulates NO release in primary rat microglial cells. (A) EP2 expression in primary rat microglial cells.
Immunofluorescent staining of EP2 and CD11b, as well as the nuclear stain DAPI are shown (scale bar, 25 μm). (B) cAMP accumulation in rat
microglia cells left untreated or treated with butaprost (10 μM) or AH6809 (10 μM) for 3 h (n = 3). (C) Butaprost stimulated NO production in
resting microglia. Primary rat microglial cells were stimulated with different concentrations of butaprost (0, 0.1, 1, 10 μM) for 24 h. At the end of
the incubation period, the supernatants were collected for NO measurements. (D) AH6809 suppressed NO production in LPS-activated microglia.
Primary rat microglial cells were unstimulated or stimulated with LPS (0.01 μg/mL) in the presence or absence of AH6809 (0.1, 1, 10 μM) for 24 h.
At the end of the incubation period, the supernatants were collected for NO measurements. ***P < 0.001 and ##P < 0.01.
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resting rat microglia was increased more than tenfold
after 200 nM and 2 μM butaprost treatment [36]. An-
other EP2 agonist, ONO-AE1-259 was also reported to
increase iNOS mRNA level in ileal tissue [37]. By con-
trast, AH6809 inhibited LPS-induced NO synthesis
(Figure 3D). Since NO levels in the medium are also af-
fected by proliferation and death of the treated micro-
glia, we observed the cell viability after EP2 agonist and
antagonist and the PKA agonist and antagonist treat-
ment in BV2 cells and found no changes (Additional file 1:
Figure S1). Thus, under an innate inflammatory stimulus,
microglia EP2 signaling potentiated a classically activated
proinflammatory response, inducing NO production.
To evaluate the involvement of the EP2 pathway in trip-
tolide’s effect, real-time PCR of EP2 was performed on a
Stratagene Mx3000P (Agilent, Santa Clara, CA, USA)
using the following parameters: 95°C for 10 min, followed
by 40 cycles at 95°C for 15 s, 60°C for 1 min, and 72°C for
1 min using the specific primer sets. The following primer
pairs were employed: 5′ - TTGCTCTTCTGTTCTCTG
CCG - 3′ (upper, 538 to 558) and 5′ - CAGCTGAAGGTA
TGCGGTCC - 3′ (lower, 642 to 623) for the amplification
of rat EP2 receptor (GenBank accession No. NM_031088)
and 5′ - ATCGCTGACAGGATGCAGAAG - 3′ (upper,
925 to 945) and 5′ - AGAGCCACCAATCCACACAGA -
3′ (lower, 1,032 to 1,012) for the amplification of rat β-
actin. Firstly, we observed the EP2 mRNA level at 1, 3, 6,
12, and 24 h after LPS induction and found that LPS aug-
mented the EP2 expression significantly at 6 h (Figure 4A).The relative expression level compared with that of resting
microglia increased to nearly 12-fold with LPS, which is
similar as that reported by Noda et al. [38]. Moreover, we
observed a prompt downregulation of EP2 mRNA level
after 12-h LPS treatment. Johansson et al. reported that
stimulation of macrophages with LPS (10 ng/ml) induced a
rapid increase in EP2 mRNA within 1 h followed by a
prompt downregulation by 6 h [39]. The different time of
EP2 mRNA upregulation between macrophages and micro-
glia maybe caused by their local microenvironment, as well
as the differences between periphery and central inflamma-
tion, but the similar changes of EP2 expression induced by
LPS indicate that EP2 expression is tightly regulated by in-
flammatory stimuli.
To investigate the effect of triptolide on LPS-regulated
EP2 expression, microglia were pretreated for 30 min
with triptolide (50 nM) and subsequently stimulated
with LPS. As shown in Figure 4B, 50 nM triptolide al-
most completely inhibited LPS-induced EP2 expression.
To confirm the triptolide inhibition of EP2 expression,
we next monitored the protein level changes of EP2 by
Western blot (Figure 4C,D). Although the changes in
EP2 protein levels were not as dramatic as were ob-
served for mRNA levels, triptolide did inhibit EP2 pro-
tein expression.
To confirm the necessary role of EP2, we treated pri-
mary rat microglial cells with butaprost/AH6809 and
triptolide before LPS stimulation. As shown in Figure 5A,
treatment with triptolide or AH6809 (10 μM) alone both
decreased NO production in LPS-treated microglia to
Figure 4 Triptolide regulates EP2 expression in LPS-stimulated microglia. (A) Rat primary microglia cells were stimulated with LPS (0.01 μg/mL)
for 0, 1, 3, 6, 12, and 24 h. The cells were lysed for EP2 expression by real-time PCR analysis. (B) Rat primary microglia cells were stimulated with LPS
(0.01 μg/mL) in the presence or absence of triptolide (50 nM) for 6 h. The cells were lysed for EP2 expression by real-time PCR analysis. (C) Primary rat
microglial cells were stimulated with LPS (0.01 μg/mL) in the presence or absence of triptolide (50 nM) for 24 h. The cells were lysed for EP2 expression
by Western blot. (D) The protein levels were quantified relative to GAPDH levels and normalized to the naïve group (untreated cells). **P< 0.01. ***P< 0.001.
##P< 0.01 and ###P< 0.001.
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Moreover, the combination of triptolide and AH6809
failed to further decrease NO production. Conversely,
the addition of butaprost (0.1 μM) partially reversed
the triptolide-induced inhibition of NO production
(Figure 5A). Taken together, these results demonstrate
that triptolide inhibits LPS-stimulated NO production
in microglia via a signaling mechanism involving EP2.
These results also indicate that triptolide regulation of
the EP2 pathway is a potential therapeutic mechanism
for the treatment of inflammation-related neurological
disorders.
EP2 activation leads to increased levels of cytoplasmic
cAMP, which then initiates multiple downstream events via
the PKA or Epac pathways. To differentiate between these
two pathways, we added the PKA-specific activator 6-Bnz-
cAMP (6Bnz) or the Epac-specific activator 8-pCPT-2-O-
Me-cAMP (8-CPT) to triptolide-treated microglia. We
found that 6Bnz (10 μM) but not 8-CPT (10 μM) in-
creased NO production in triptolide-LPS treated microglia
(Figure 5B), indicating that EP2-PKA was mainly involved
in the triptolide inhibition. This specificity was most likely
due to the nature of LPS stimulation. Peters-Golden et al.
reported that in rat alveolar macrophages, the down-
modulation of LPS-induced TNF-α by PGE2 is dependent
on cAMP-PKA activation. This was concluded given that
the selective PKA activating cAMP analog 6Bnz but notthe Epac-1 activating analog 8-CPT inhibited TNF-α pro-
duction [40]. Their recent work also indicates that EP2-
PKA, rather than Epac-1, is involved in the enhancement
of LPS-induced NO [41]. This result suggests that the EP2-
PKA pathway is very important for the anti-inflammatory
effect of triptolide in microglia. More studies are needed to
clarify whether the EP2-PKA signaling pathway is the
dominant mediator of harmful EP2-mediated effects in
microglia.
We further observe this effect in BV2 cells, and found
6Bnz (10 μM) increased NO production in triptolide-
LPS treated microglia (Figure 5C). To confirm that PKA
is indeed responsible for the inhibition of NO generation
by triptolide, BV2 cells were pre-treated with the PKA
inhibitor KT5720, and the PKA-specific activator 6Bnz
was added before triptolide treatment. We found that
6Bnz (10 μM) increased NO production in triptolide-
LPS treated microglia, KT5720 attenuated NO produc-
tion to an extent similar to that observed with triptolide
treatment (Figure 5C), suggesting that PKA is respon-
sible for the triptolide inhibition.
The direct target of triptolide in the regulation of EP2-
PKA pathway remains unknown. Liu et al. report that
triptolide directly binds to human XPB, a subunit of the
transcription factor TFIIH, leading to the inhibition of
RNA polymerase II-mediated transcription in tumor cells
[42]. However, these authors used higher concentrations
Figure 5 EP2-PKA pathway is important in LPS-stimulated NO production and triptolide inhibition. (A) Primary rat microglial cells were
treated with LPS (0.01 μg/mL), LPS plus AH6809 (10 μM), LPS plus triptolide (50 nM), LPS plus triptolide plus AH6809, and LPS plus triptolide plus
butaprost (0.1 μM) for 24 h. At the end of the incubation period, the supernatants were collected for NO measurements. (B) Primary rat microglial cells
were treated with LPS (0.01 μg/mL), LPS plus triptolide (50 nM), LPS plus triptolide plus butaprost (0.1 μM), LPS plus triptolide plus 8-CPT (10 μM), or
LPS plus triptolide plus 6Bnz (10 μM) for 24 h. At the end of the incubation period, the supernatants were collected for NO measurements. (C) BV2 cells
were treated with LPS (0.01 μg/mL), LPS plus triptolide (50 nM), LPS plus triptolide plus 6Bnz (10 μM), and LPS plus triptolide plus 6Bnz (10 μM) plus
KT5720 (1 μM) for 24 h. At the end of the incubation period, the supernatants were collected for NO measurements. *P < 0.05 and ***P < 0.001.
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tion. We used lower concentrations of triptolide (no more
than 50 nM) to suppress inflammation and to protect neu-
rons in the brain. Therefore, different targets may exist for
triptolide with respect to the modulation of the inflamma-
tory response in the CNS. Recently, Shen et al. reported
that triptolide inhibited TAK1 kinase activity by interfering
with the formation of the TAK1-TAB1 complex, and that
the binding affinity of triptolide to TAB1 was highly corre-
lated with the inhibitory activity of triptolide against the
MAPK pathway activation in macrophages [23]. Although
macrophages and microglia are both tissue-resident immune
cells during inflammation and the effective triptolide concen-
tration was similar in both cell types, it remains to be investi-
gated whether TAB1 is the target of triptolide in microglia.
Conclusions
The present study demonstrates that triptolide inhibits
LPS-stimulated NO production in microglia via a signaling
mechanism involving EP2 and PKA. The finding that trip-
tolide reduces the proinflammatory factors in microglia andprotects neurons from inflammatory stimulation may help
establish the pharmacological function of triptolide in neu-
rodegenerative disorders. Moreover, the observation of in-
flammatory EP2 signaling in primary microglia also
provides important evidence with respect to EP2 in the
regulation of innate immunity in the CNS.
Additional file
Additional file 1: Figure S1. Microglia proliferations did not change after
pharmacological treatments. BV2 cells treated with butaprost (0.1 μM),
AH6809 (10 μM), 8-CPT (10 μM), 6Bnz (10 μM), KT5720 (1 μM), and DMSO
(0.1%) for 24 h. Cell viability was assessed by MTS assay.
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